Aug. 17 at 3:36 PM
Precipio, Inc. (NASDAQ:
$PRPO ) reported revenue of
$7.0 million for the second quarter ended June 30, 2026, the highest quarterly revenue in the company’s history and an increase of 22% from
$5.7 million in the second quarter of 2025. The specialty cancer diagnostics company validates its technologies clinically in its own laboratory before commercializing them for the global laboratory community.
Precipio, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/precipio-inc-1
Both sides of the business contributed, with pathology services and diagnostic products each growing sequentially:
• Revenue surpassed
$7 million for the first time in company history, rising from
$6.7 million in the first quarter
• Product revenue reached
$0.9 million, an increase of 21% over the previous high of
$750,000 in the fourth quarter of 2025, and pathology revenue reached
$6.1 million
• Adjusted EBITDA, a non-GAAP measure the company reconciles in the release, was positive at
$0.4 million for the quarter
• Cash flow from operations was
$0.7 million, and cash ended the quarter above
$3 million against
$1.1 million a year earlier
• Management will discuss the quarter on a shareholder call on August 17, 2026 at 5 p.m. ET, followed by a moderated question and answer session
The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call.
Regarding the cash balance, Ilan Danieli, Chief Executive Officer of Precipio, stated: “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.”
Read the full release: https://www.precipiodx.com/precipio-announces-q2-2026-financial-results/
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, then commercializes them as proprietary products that serve the global laboratory community. More information is available at https://www.precipiodx.com. Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
$EXAS,
$NTRA,
$GH,
$XBI